Cargando…
LBODP100 A Rare Case Of Pembrolizumab Induced Graves’ Disease
Cancer immunotherapies have recently changed the therapeutic armamentarium of anti-cancer treatments, particularly for melanoma and cancers of the kidneys, lungs, and colon. Immune checkpoint inhibitors (ICPis) act on various immune checkpoints. Of them, anti-PD-1 antibodies (such as pembrolizumab)...
Autores principales: | Alqaisi, Sura, Rahman, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625739/ http://dx.doi.org/10.1210/jendso/bvac150.1529 |
Ejemplares similares
-
A Rare Case of Pembrolizumab-Associated Graves’ Disease
por: Alqaisi, Sura, et al.
Publicado: (2023) -
LBODP064 A Rare Case Of Paraneoplastic Cushing Syndrome Associated With Pulmonary Carcinoid Tumor
por: Mandal, Gaurav, et al.
Publicado: (2022) -
SAT-584 Pembrolizumab-Related Graves' Disease: A Rare Adverse Effect of an Anti-PD-1 Antibody Cancer Immunotherapy
por: Narayen, Garima, et al.
Publicado: (2019) -
LBODP096 High Failure Rate Of Radioactive Iodine-131 (Rai) Therapy For The Treatment Of Grave's Disease And Toxic Multinodular Goiter In An Urban Municipal Hospital Clinic
por: Handoo, Maryam Manzoor, et al.
Publicado: (2022) -
A Rare Case of Rhabdomyolysis in a Patient With Pembrolizumab Induced Hypothyroidism
por: Idriss, Setana, et al.
Publicado: (2021)